MARLBOROUGH, Mass. (Dow Jones/AP) -- Sepracor Inc. (SEPR) said Paul Rubin, executive vice president, research and development, resigned to pursue other opportunities, effective Sept. 1. In a press ...

Mark Iwicki, the new president and COO at Sepracor, says the company, under new Japanese ownership, will focus on niche market drugs. PHOTO/COURTESY The $2.6 billion move for Dainippon Sumitomo Pharma ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. and Dainippon Sumitomo Pharma Co., Ltd. (DSP) today announce the resignation of Adrian Adams as President and Chief Executive Officer and Director of ...

Japanese pharmaceutical giant Dainippon Sumitomo Pharma Co. has completed its $2.6 billion acquisition of Sepracor Inc., triggering change-in-control provisions at the local drug maker that could ...

Firm will provide commercialization infrastructure in the U.S. and Canada for Japanese-based DSP. Dainippon Sumitomo Pharma (DSP) is willing to pay $2.6 billion to take over Sepracor. The purchase ...

Submission includes data from three Phase III studies in over 1,000 patients from 23 countries Represents Sepracor's first NDS in Canada since strategic acquisition of Oryx Pharmaceuticals in June ...

BNET -- Sepracor began the year by announcing the layoffs of about 940 staff — 530 of its own reps and execs and 410 contract reps. But the pain wasn’t felt equally at Sepracor. Top management at the ...

MARLBOROUGH, Mass. Drug maker Sepracor might get tax breaks for building in its hometown. The MetroWest Daily News reports that the company is constructing new buildings in Marlborough, Mass., and ...

NEW YORK (Reuters) - Sepracor Inc said on Thursday late-stage studies of its experimental epilepsy treatment showed a significant reduction in partial seizures when the product was given along with ...

NEW YORK Marlborough, Mass.-based pharmaceutical company Sepracor has shelled out $50 million for a Canadian drug manufacturer, Sepracor announced Tuesday. Sepracor bought Canada’s Oryx ...

Agreements cover a company acquisition for $50 million and rights to enhance brand management within its respiratory disease portfolio. Sepracor reports multiple deals with the Arrow Group, including ...

Agreement provides Sepracor with a global license covering development of stable suspension formulations and nebule technology in ciclesonide inhalation solution for asthma and chronic obstructive ...